Company news
Alector, Inc. (NASDAQ:ALEC) news
Alector, Inc. news releases on 6ix. Latest, Oct 5, 2026: Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement…
Press releases & updates
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
October 5, 2026
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
April 29, 2026
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
February 23, 2026
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
December 11, 2025
Alector to Participate in the Bank of America CNS Therapeutics Conference
November 30, 2025
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
October 20, 2025
Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs
September 15, 2025
Alector to Participate in Upcoming Healthcare Conferences
August 27, 2025
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
July 30, 2025
Alector Provides Executive Leadership Update
June 12, 2025
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 2, 2025
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease
April 16, 2025
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 25, 2025
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
February 18, 2025
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
January 12, 2025
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
November 24, 2024
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
November 13, 2024
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
November 5, 2024
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
September 18, 2024
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
August 6, 2024
Alector to Host Mid-Year Earnings Conference Call
July 30, 2024
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
July 27, 2024
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
July 22, 2024
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 19, 2024
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
June 9, 2024
Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 2, 2024
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
May 7, 2024
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 26, 2024
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
February 19, 2024
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
February 7, 2024
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
February 6, 2024
Alector Announces Closing of Public Offering
January 18, 2024
Alector Announces Pricing of Public Offering of Common Stock
January 16, 2024
Alector Announces Proposed Public Offering of Common Stock
January 15, 2024
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
November 27, 2023
Alector to Participate in the Stifel Healthcare Conference
November 7, 2023
Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
November 6, 2023
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
October 26, 2023
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
September 6, 2023
Alector Reports Second Quarter 2023 Financial Results and Provides Business Update
August 2, 2023
Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 5, 2023
Alector Reports First Quarter 2023 Financial Results and Provides Business Update
May 3, 2023
Alector to Participate in the BofA Securities 2023 Healthcare Conference
May 1, 2023
Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 27, 2023